Solence, founded by Clara Stephenson in 2022, is developing an AI-powered healthcare app aimed at women with PCOS, the most common hormonal disorder affecting 1 in 7 women globally, inspired by her own decade-long struggle with undiagnosed PCOS.

Supported by investors like Céline Lazorthes, Solence aims to reach millions of women and significantly improve their health and wellbeing through personalized digital solutions.

Clara Stephenson's personal experience with undiagnosed PCOS motivated her to create Solence to raise awareness and promote better management of this often underdiagnosed and undertreated condition.

The app's scientific credibility is reinforced by a board including Professor Michel Pugeat and Dr. Nour Mimouni, emphasizing the multidisciplinary approach to tackling PCOS.

The digital app offers interactive lessons, monthly assessment scores, and personalized advice, helping women identify triggers and manage symptoms through evidence-based lifestyle changes.

Moving beyond medication, the app provides tailored guidance to help women manage and potentially reverse PCOS symptoms by tracking symptoms and offering data-driven insights.

The app's personalized approach adapts to individual needs, utilizing scientific research and expert input to support symptom management and lifestyle modifications.

While traditional treatments for PCOS often rely on medication, current guidelines recommend lifestyle and behavioral interventions as primary strategies, which Solence's app aims to facilitate.

The company's first product is a 12-week digital program focused on lifestyle interventions to help women manage PCOS symptoms, improve fertility, and enhance overall quality of life.

PCOS affects up to 20% of women worldwide, yet 85% do not receive adequate support due to high costs, misinformation, and the complexity of symptoms like weight gain, irregular periods, and mental health issues.

A recent funding round supported by Impact Shakers Ventures and angel investors, including Céline Lazorthes, will be used to expand app features, grow the team, and develop clinical partnerships to increase access and impact.